Blake Cannon1, David L Schwartz, Lei Dong. 1. Department of Radiation Physics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
Abstract
PURPOSE: Xerostomia is a major complication of head and neck radiotherapy (RT). Available xerostomia measures remain flawed. [(18)F]fluorodeoxyglucose-labeled positron emission tomography-computed tomography (FDG-PET-CT) is routinely used for staging and response assessment of head and neck cancer. We investigated quantitative measurement of parotid gland FDG uptake as a potential biomarker for post-RT xerostomia. METHODS AND MATERIALS: Ninety-eight locally advanced head and neck cancer patients receiving definitive RT underwent baseline and post-RT FDG-PET-CT on a prospective imaging trial. A separate validation cohort of 14 patients underwent identical imaging while prospectively enrolled in a second trial collecting sialometry and patient-reported outcomes. Radiation dose and pre- and post-RT standard uptake values (SUVs) for all voxels contained within parotid gland ROI were deformably registered. RESULTS: Average whole-gland or voxel-by-voxel models incorporating parotid D(Met) (defined as the pretreatment parotid SUV weighted by dose) accurately predicted posttreatment changes in parotid FDG uptake (e.g., fractional parotid SUV). Fractional loss of parotid FDG uptake closely paralleled early parotid toxicity defined by posttreatment salivary output (p < 0.01) and Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer xerostomia scores (p < 0.01). CONCLUSIONS: In this pilot series, loss of parotid FDG uptake was strongly associated with acute clinical post-RT parotid toxicity. D(Met) may potentially be used to guide function-sparing treatment planning. Prospective validation of FDG-PET-CT as a convenient, quantifiable imaging biomarker of parotid function is warranted and ongoing.
PURPOSE:Xerostomia is a major complication of head and neck radiotherapy (RT). Available xerostomia measures remain flawed. [(18)F]fluorodeoxyglucose-labeled positron emission tomography-computed tomography (FDG-PET-CT) is routinely used for staging and response assessment of head and neck cancer. We investigated quantitative measurement of parotid gland FDG uptake as a potential biomarker for post-RT xerostomia. METHODS AND MATERIALS: Ninety-eight locally advanced head and neck cancerpatients receiving definitive RT underwent baseline and post-RT FDG-PET-CT on a prospective imaging trial. A separate validation cohort of 14 patients underwent identical imaging while prospectively enrolled in a second trial collecting sialometry and patient-reported outcomes. Radiation dose and pre- and post-RT standard uptake values (SUVs) for all voxels contained within parotid gland ROI were deformably registered. RESULTS: Average whole-gland or voxel-by-voxel models incorporating parotid D(Met) (defined as the pretreatment parotid SUV weighted by dose) accurately predicted posttreatment changes in parotid FDG uptake (e.g., fractional parotid SUV). Fractional loss of parotid FDG uptake closely paralleled early parotid toxicity defined by posttreatment salivary output (p < 0.01) and Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer xerostomia scores (p < 0.01). CONCLUSIONS: In this pilot series, loss of parotid FDG uptake was strongly associated with acute clinical post-RT parotid toxicity. D(Met) may potentially be used to guide function-sparing treatment planning. Prospective validation of FDG-PET-CT as a convenient, quantifiable imaging biomarker of parotid function is warranted and ongoing.
Authors: Michael C Roach; Timothy G Turkington; Kristin A Higgins; Thomas C Hawk; Jenny K Hoang; David M Brizel Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-27 Impact factor: 7.038
Authors: J J Pavy; J Denekamp; J Letschert; B Littbrand; F Mornex; J Bernier; D Gonzales-Gonzales; J C Horiot; M Bolla; H Bartelink Journal: Int J Radiat Oncol Biol Phys Date: 1995-03-30 Impact factor: 7.038
Authors: He Wang; Lei Dong; Jennifer O'Daniel; Radhe Mohan; Adam S Garden; K Kian Ang; Deborah A Kuban; Mark Bonnen; Joe Y Chang; Rex Cheung Journal: Phys Med Biol Date: 2005-06-01 Impact factor: 3.609
Authors: Antonius W T Konings; Hette Faber; Femmy Cotteleer; Arjan Vissink; Rob P Coppes Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-13 Impact factor: 7.038
Authors: Susan L Tucker; Rex Cheung; Lei Dong; H Helen Liu; Howard D Thames; Eugene H Huang; Deborah Kuban; Radhe Mohan Journal: Int J Radiat Oncol Biol Phys Date: 2004-06-01 Impact factor: 7.038
Authors: Judith M Roesink; Marinus A Moerland; Anne Hoekstra; Peter P Van Rijk; Chris H J Terhaard Journal: Int J Radiat Oncol Biol Phys Date: 2004-04-01 Impact factor: 7.038
Authors: Jerry L Barker; Adam S Garden; K Kian Ang; Jennifer C O'Daniel; He Wang; Laurence E Court; William H Morrison; David I Rosenthal; K S Clifford Chao; Susan L Tucker; Radhe Mohan; Lei Dong Journal: Int J Radiat Oncol Biol Phys Date: 2004-07-15 Impact factor: 7.038
Authors: Joel R Wilkie; Michelle L Mierzwa; Keith A Casper; Charles S Mayo; Matthew J Schipper; Avraham Eisbruch; Francis P Worden; Issam El Naqa; Benjamin L Viglianti; Benjamin S Rosen Journal: Radiother Oncol Date: 2020-04-06 Impact factor: 6.280
Authors: Anju Gangadharan; Sung Eun Choi; Ahmed Hassan; Nehad M Ayoub; Gina Durante; Sakshi Balwani; Young Hee Kim; Andrew Pecora; Andre Goy; K Stephen Suh Journal: Oncotarget Date: 2017-04-04
Authors: Hesham Elhalawani; Carlos E Cardenas; Stefania Volpe; Souptik Barua; Sonja Stieb; Calvin B Rock; Timothy Lin; Pei Yang; Haijun Wu; Jhankruti Zaveri; Baher Elgohari; Lamiaa E Abdallah; Amit Jethanandani; Abdallah S R Mohamed; Laurence E Court; Katherine A Hutcheson; G Brandon Gunn; David I Rosenthal; Steven J Frank; Adam S Garden; Arvind Rao; Clifton D Fuller Journal: Clin Transl Radiat Oncol Date: 2021-06-06